{"id":76,"date":"2025-04-14T11:44:13","date_gmt":"2025-04-14T09:44:13","guid":{"rendered":"https:\/\/archivio.smc-media.eu\/inhibitors2016\/?page_id=76"},"modified":"2025-04-14T11:48:57","modified_gmt":"2025-04-14T09:48:57","slug":"programme","status":"publish","type":"page","link":"https:\/\/archivio.smc-media.eu\/inhibitors2016\/programme\/","title":{"rendered":"Programme"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_code admin_label=&#8221;.titoli&#8221; module_class=&#8221;titoli&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<pee>PROGRAMME<\/pee>[\/et_pb_code][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_2,1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_code admin_label=&#8221;.titoli&#8221; module_class=&#8221;titoli&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<pee>Friday, March 4<sup>th<\/sup> 2016<\/pee>[\/et_pb_code][et_pb_code _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">09:00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">10:00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSTART\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Mechanisms of inhibitor development<\/pee><!-- [et_pb_line_break_holder] --><pee><span style=\"color: #00a4d9;\">Chair:<\/span> <em>Sebastien Lacroix Desmazes (France)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Allo and autoantibodies<a href=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/pdf\/Lacroix.pdf\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/img\/icon_pdf.png\" style=\"height:17px; width:auto; margin-left: 5px;\"><\/a><\/pee><!-- [et_pb_line_break_holder] --><pee><em>Sebastien Lacroix Desmazes (France)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">The role of B and T cells and novel therapeutical approach<a href=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/pdf\/Scott_mn.pdf\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/img\/icon_pdf.png\" style=\"height:17px; width:auto; margin-left: 5px;\"><\/a><\/pee><!-- [et_pb_line_break_holder] --><pee><em>David W Scott (USA)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\">Discussion<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/p>\n<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">10:00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">11:00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSTART\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Inhibitor data collection systems<\/pee><!-- [et_pb_line_break_holder] --><pee><span style=\"color: #00a4d9;\">Chair:<\/span> <em>Mike Makris (UK)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">National registries: UK, French, Canadian<a href=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/pdf\/Goudemand.pdf\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/img\/icon_pdf.png\" style=\"height:17px; width:auto; margin-left: 5px;\"><\/a><\/pee><!-- [et_pb_line_break_holder] --><pee><em>Jenny Goudemand (France)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">European data collections on previosuly untreated patients (PUPs)<\/pee><!-- [et_pb_line_break_holder] --><pee><em>Marijke van den Berg (the Netherlands)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Inhibitors in previously treated patients (PTP)<\/pee><!-- [et_pb_line_break_holder] --><pee><em>Mike Makris (UK)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\">Discussion<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/p>\n<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">11:30<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">12:30<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSTART\"><span style=\"color: #00a4d9;\">Chair:<\/span> <em>Marijke van den Berg (the Netherlands)<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Inhibitors in mild hemophilia. INSIGHT study<\/pee><!-- [et_pb_line_break_holder] --><pee><em>Alice S. van Velzen (the Netherlands)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\">Discussion<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Clinical significance of low and high titer inhibitors<a href=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/pdf\/Santagostino.pdf\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/img\/icon_pdf.png\" style=\"height:17px; width:auto; margin-left: 5px;\"><\/a><\/pee><!-- [et_pb_line_break_holder] --><pee><em>Elena Santagostino (Italy)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\">Discussion<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/p>\n<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">14:00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">15:30<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSTART\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Inhibitor development in previoiusly untreated patients (PUPs)<\/pee><!-- [et_pb_line_break_holder] --><pee><span style=\"color: #00a4d9;\">Chair:<\/span> <em>Keith W. Hoots (USA)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Role of von Willebrand factor for concentrate immunogenicity<a href=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/pdf\/Lillicrap_1.pdf\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/img\/icon_pdf.png\" style=\"height:17px; width:auto; margin-left: 5px;\"><\/a><\/pee><!-- [et_pb_line_break_holder] --><pee><em>David Lillicrap (Canada)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Results of SIPPET study<\/pee><!-- [et_pb_line_break_holder] --><pee><em>Frits R. Rosendaal (the Netherlands)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">How EMA and FDA are tackling the problem of inhibitor development<\/pee><!-- [et_pb_line_break_holder] --><pee><em>Anneliese Hilger (EMA)<\/em> and <em>Jay Epstein, Zuben E. Sauna (FDA)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\">Discussion<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/p>\n<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">15:30<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">16:00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSTART\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Genetics of inhibitors. How next generation sequencing can help to better understand the inhibitor risk<\/pee><!-- [et_pb_line_break_holder] --><pee><span style=\"color: #00a4d9;\">Chair:<\/span> <em>Elena Santagostino (Italy)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Johannes Oldenburg (Germany)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Discussion<\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/p>\n<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">16:20<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">16:40<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSTART\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Cost of inhibitor treatment. A pharmacoeconomical perspective<\/pee><!-- [et_pb_line_break_holder] --><pee><span style=\"color: #00a4d9;\">Chair:<\/span> <em>Frits R. Rosendaal (the Netherlands)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Lorenzo Mantovani (Italy)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Discussion<\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/p>\n<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">16:40<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">17:20<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSTART\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Treatment of inhibitors<\/pee><!-- [et_pb_line_break_holder] --><pee><span style=\"color: #00a4d9;\">Chair:<\/span> <em>Flora Peyvandi (Italy)<\/em> and <em>David Lillicrap (Canada)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Our experience on bypassing therapy in patients with inhibitors. Success and failures: what else is necessary?<a href=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/pdf\/Mancuso.pdf\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/img\/icon_pdf.png\" style=\"height:17px; width:auto; margin-left: 5px;\"><\/a><\/pee><!-- [et_pb_line_break_holder] --><pee><em>Maria Elisa Mancuso (Italy)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">The role of non replacement products (antithrombin, anti TFPI, bi-specific antibody)<\/pee><!-- [et_pb_line_break_holder] --><pee><em>David Lillicrap (Canada)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/p>\n<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">17:20<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">18:00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSTART\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Optimal diagnosis and treatment of patients with acquired hemophilia<\/pee><!-- [et_pb_line_break_holder] --><pee><span style=\"color: #00a4d9;\">Chair:<\/span> <em>Pier Mannuccio Mannucci (Italy)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Craig Kessler (USA)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] -->Discussion<\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p>[\/et_pb_code][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_code admin_label=&#8221;.titoli&#8221; module_class=&#8221;titoli&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<pee>Saturday, March 5<sup>th<\/sup> 2016<\/pee>[\/et_pb_code][et_pb_code _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">09:00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">10:20<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSTART\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Eradication of inhibitor by Immune Tolerance Induction (ITI): What we know and what we need to know<\/pee><!-- [et_pb_line_break_holder] --><pee><span style=\"color: #00A4D9;\">Chair:<\/span> <em>Giovanni Di Minno (Italy)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Eradication of allo-antibodies. International data<a href=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/pdf\/Hay.pdf\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/img\/icon_pdf.png\" style=\"height:17px; width:auto; margin-left: 5px;\"><\/a><\/pee><!-- [et_pb_line_break_holder] --><pee><em>Charles R.M. Hay (UK)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Eradication of autoantibodies<a href=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/pdf\/Knobl.pdf\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/img\/icon_pdf.png\" style=\"height:17px; width:auto; margin-left: 5px;\"><\/a><\/pee><!-- [et_pb_line_break_holder] --><pee><em>Andreas Tiede (Germany), Paul Knoebl (Austria)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Italian ITI experience<\/pee><!-- [et_pb_line_break_holder] --><pee><em>Giovanni Di Minno (Italy)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\">Discussion<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/p>\n<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">10:20<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">11:00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSTART\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Future NIH programmes for the prevention of inhibitors<a href=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/pdf\/Hoots.pdf\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/img\/icon_pdf.png\" style=\"height:17px; width:auto; margin-left: 5px;\"><\/a><\/pee><!-- [et_pb_line_break_holder] --><pee><span style=\"color: #00A4D9;\">Chair:<\/span> <em>Frits R. Rosendaal (the Netherlands)<\/em><!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>Donna DiMichele (USA)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\">Discussants: <em>David Lillicrap<\/em> and <em>Frits R. Rosendaal<\/em><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/p>\n<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">11:20<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">12:00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSTART\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Patients views and expectations: What initiatives are WFH and EHC planning for inhibitors?<\/pee><!-- [et_pb_line_break_holder] --><pee><em>Pier Mannuccio Mannucci (Italy)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">European Hemophilia Consortium<a href=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/pdf\/Milan_Amanda-Bok.pdf\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/img\/icon_pdf.png\" style=\"height:17px; width:auto; margin-left: 5px;\"><\/a><\/pee><!-- [et_pb_line_break_holder] --><pee><em>Amanda Bok (Belgium)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">World Federation of Hemophilia<a href=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/pdf\/Brooker_compressed.pdf\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/archivio.smc-media.eu\/inhibitors2016\/img\/icon_pdf.png\" style=\"height:17px; width:auto; margin-left: 5px;\"><\/a><\/pee><!-- [et_pb_line_break_holder] --><pee><em>Alain Weill (Canada)<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p><!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] --><\/p>\n<table width=\"100%\" cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><!-- [et_pb_line_break_holder] --><\/p>\n<tbody><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">12:00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdorariSTART\">13:00<\/td>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<td class=\"tdSTART\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Round Table Discussion: Benefit of fewer inhibitors? A formidable issue<\/pee><!-- [et_pb_line_break_holder] --><pee><span style=\"color: #00A4D9;\">Moderator:<\/span> Flora Peyvandi<!\u2013- [et_pb_br_holder] -\u2013><!-- [et_pb_line_break_holder] --><em>P.M. Mannucci, D. Lillicrap, D. DiMichele, J. Goudemand, F.R. Rosendaal, K. Hoots, A. Bok, A. Weill<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/p>\n<tr><!-- [et_pb_line_break_holder] --><\/p>\n<td colspan=\"3\"><!-- [et_pb_line_break_holder] --><pee class=\"PRtitoli\">Conclusive remarks<\/pee><!-- [et_pb_line_break_holder] --><pee><em>F. Peyvandi and P.M.Mannucci<\/em><\/pee><\/td>\n<p><!-- [et_pb_line_break_holder] --><\/tr>\n<p><!-- [et_pb_line_break_holder] --><\/tbody>\n<p><!-- [et_pb_line_break_holder] --><\/table>\n<p>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-76","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/archivio.smc-media.eu\/inhibitors2016\/wp-json\/wp\/v2\/pages\/76","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/archivio.smc-media.eu\/inhibitors2016\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/archivio.smc-media.eu\/inhibitors2016\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/archivio.smc-media.eu\/inhibitors2016\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/archivio.smc-media.eu\/inhibitors2016\/wp-json\/wp\/v2\/comments?post=76"}],"version-history":[{"count":4,"href":"https:\/\/archivio.smc-media.eu\/inhibitors2016\/wp-json\/wp\/v2\/pages\/76\/revisions"}],"predecessor-version":[{"id":82,"href":"https:\/\/archivio.smc-media.eu\/inhibitors2016\/wp-json\/wp\/v2\/pages\/76\/revisions\/82"}],"wp:attachment":[{"href":"https:\/\/archivio.smc-media.eu\/inhibitors2016\/wp-json\/wp\/v2\/media?parent=76"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}